假性剥脱性青光眼的生物标志物研究进展  

Research progress on biomarkers of pseudoexfoliative glaucoma

作　　者：黄悦 李妍[2] 包郑伊琳 李玉婷 喻永沅 胡竹林 Yue Huang;Yan Li;Zheng-Yi-Lin Bao;Yu-Ting Li;Yong-Yuan Yu;Zhu-Lin Hu(Kunming Medical University,Kunming 650500,Yunnan Province,China;Department of Ophthalmology,Yunnan University Affiliated Hospital,Kunming 650000,Yunnan Province,China)

机构地区：[1]昆明医科大学,中国云南省昆明市650500 [2]云南大学附属医院眼科,中国云南省昆明市650000

出　　处：《国际眼科杂志》2023年第7期1134-1138,共5页International Eye Science

基　　金：云南省科技厅科技计划项目(No.202201AT070073);云南省基础研究专项昆医联合专项(No.202001AY070001-165)。

摘　　要：假性剥脱性青光眼(PEXG)是一种严重危害视力的眼部疾病,较原发性开角型青光眼(POAG)更具侵袭性,对视神经的损害更严重,预后更差,且对治疗有较高的耐药性。早期诊断PEXG有助于及时治疗,并延缓疾病进展,因此确定适当的生物标志物至关重要。近几年来,越来越多的人开始研究PEXG的生物标志物,希望通过基因组学、转录组学、蛋白组学、代谢组学以及脂质组学标志物的研究,了解该病的发病机制,寻找PEXG潜在的早期诊断和治疗靶点,对该疾病提供一定帮助。本文将对近几年PEXG的生物标志物研究进展进行阐述,其中一些生物标志物可能在未来对PEXG的早期诊断提供新思路。Pseudoexfoliative glaucoma (PEXG) is an eye disease that seriously endangers vision.It is more invasive than primary open-angle glaucoma (POAG),with more serious damage to the optic nerve,worse prognosis and higher resistance to treatment.Early diagnosis of PEXG can help to treat the disease in time and delay the progress of the disease,so it is important to determine appropriate biomarkers.In recent years,more and more people have begun to study the biomarkers of PEXG,hoping to understand the pathogenesis of the disease,find out the potential early diagnosis and treatment targets of PEXG,and provide some help to the disease through the research of genomics,transcriptomics,proteomics,metabolomics and lipomics markers.This article will review the progress of biomarkers of PEXG in recent years,some biomarkers may provide new ideas for early diagnosis of PEXG in the future.

关 键 词：假性剥脱性青光眼 生物标志物 基因组学 蛋白组学 代谢组学 

分 类 号：R775[医药卫生—眼科]